Why Ampol, Cann, Fortescue, & Mesoblast shares are surging higher

Cann Group Ltd (ASX:CAN) and Mesoblast limited (ASX:MSB) shares are two of four surging higher on Monday. Here’s why…
The post Why Ampol, Cann, Fortescue, & Mesoblast shares are surging higher appeared first on Motley Fool Australia. –

shares higher, growth shares

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) is defying Friday’s weakness on Wall Street and is pushing higher. At the time of writing, the benchmark index is up 0.5% to 6,573.3 points.

Four shares that are climbing more than most today are listed below. Here’s why they are surging higher:

Ampol Ltd (ASX: ALD)

The Ampol share price is jumping higher after announcing an off-market share buyback worth $300 million. The fuel retailer announced the surprise buyback after completing the sale of its convenience retail properties. Originally, the company, which was formerly known as Caltex, was going to use the funds to reduce its debt leverage. But due to improving trading conditions, management has opted to use the proceeds to buy back shares as well.

Cann Group Ltd (ASX: CAN)

The Cann share price is up 3% to 35 cents after announcing a new bank facility. According to the release, the cannabis company has received credit approval from National Australia Bank Ltd (ASX: NAB) for a $50 million secured debt facility. The company expects to complete the execution of documentation with the banking giant within the next month.

Fortescue Metals Group Limited (ASX: FMG)

The Fortescue share price has stormed 5% higher to $17.79. This is despite there being no news out of the iron ore producer. However, a number of resources shares are on the rise today and are playing a key role in driving the ASX 200 higher. The S&P/ASX 200 Resources index is up 2.1% at the time of writing.

Mesoblast limited (ASX: MSB)

The Mesoblast share price has continued its positive run and is up a further 6.5% to $3.88. Investors have been buying the biotech company’s shares after it announced a major deal with pharma giant Novartis at the end of last week. The two companies have signed an exclusive worldwide license and collaboration agreement for the development, manufacture, and commercialisation of Mesoblast’s mesenchymal stromal cell (MSC) product remestemcel-L. Novartis will pay US$50 million upfront and could then pay over US$1.25 billion in milestone payments to Mesoblast.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why Ampol, Cann, Fortescue, & Mesoblast shares are surging higher appeared first on Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!